JL, What you seems to suggest is that tier>price>generic at pharmacy, correct? What do other board pharmacists think? Also, if it comes down to price, why wouldn't NDA holder win in many if not most cases based on their volume driven cost?
JL: this is a major issue that will be even more relevant if the patent appeal against the generics does not go AMRN's way. In order to be able to enforce R-I patents AMRN would need to be able to prove that they are being infringed upon. In your scenario, how would AMRN ever know if generics are being filled under a R-I indication ? According to the pharmacists, no one except the doctor will know the reason the script is being written.
News 
Market Data 
Discover 
